Chiron/Organon Teknika
This article was originally published in The Gray Sheet
Executive Summary
Firms ink semi-exclusive, worldwide license for patents relating to the development of assays for detection of HIV in nucleic acid sequences in clinical diagnostics, excluding blood screening. Organon is the third licensee of the patents, including Bayer AG and Roche. Chiron will receive royalty payments based on a percentage of net sales of current and future Organon Teknika offerings, subject to minimum royalties as a fixed amount per test sold